ALA

Alpha-lipoic acid is an organosulfur molecule built around a five-membered dithiolane ring containing two sulfur atoms, and it is derived biosynthetically from the fatty acid octanoic acid ^[2]. In its natural, protein-bound form it is an indispensable cofactor for mitochondrial enzyme complexes such as pyruvate dehydrogenase and α-ketoglutarate dehydrogenase, which link the breakdown of glucose to the citric acid cycle and cellular energy production ^[2]. The body makes small amounts endogenously, and it is present in foods bound to protein, but supplemental ALA is chemically synthesized and taken as the free acid ^[1][2].

ALA is unusual in dissolving in both water and lipid, which lets it act as an antioxidant across different cellular compartments; its reduced form, dihydrolipoic acid, can regenerate other antioxidants such as glutathione and vitamins C and E and can chelate metals ^[1]. Beyond simple radical scavenging, research suggests it influences signaling, including activation of the Nrf2 detoxification pathway and suppression of the inflammatory transcription factor NF-κB ^[1]. Only the R-enantiomer occurs in nature and is generally the more active form, whereas the synthetic S-enantiomer is less active; most products contain either the racemic mixture or purified R-lipoic acid ^[2]. Oral bioavailability is modest, on the order of a third of the dose, with a short half-life, which has motivated various improved formulations ^[2].

The best-studied clinical use is diabetic peripheral neuropathy. In Germany, ALA has been approved as a drug for this indication since the 1960s and is available without prescription, and it is often given intravenously in that setting ^[2]. Evidence for oral use is mixed; some meta-analyses report dose-related improvement in neuropathy symptom scores ^[3], while a Cochrane systematic review concluded that oral ALA probably has little or no effect on symptoms at six months and noted a high risk of bias in the underlying trials ^[4]. ALA has also been examined for obesity, metabolic and cardiovascular measures, and various neurological conditions, generally with modest or inconclusive results ^[1][2]. Aside from its pharmaceutical status in some countries, it is sold globally as a dietary supplement in capsules, tablets, and solutions ^[2].

Alpha-lipoic acid is a widely used antioxidant supplement that is generally well tolerated, with the most common effects being gastrointestinal upset, rash, and lowering of blood sugar that can cause hypoglycemia, particularly in people with diabetes or taking glucose-lowering medication. Rare cases of insulin autoimmune syndrome causing hypoglycemia have been reported. It may also interact with thyroid medication and chemotherapy, so combined use warrants caution.

Alpha-lipoic acid, also called thioctic acid, was first isolated in crystalline form in 1951 by Lester J. Reed and colleagues at the University of Texas, working with material derived from large quantities of liver; the achievement clarified its role as an essential cofactor in the oxidative decarboxylation reactions of energy metabolism. In the decades that followed, its dual identity became apparent: a protein-bound lipoyl cofactor for mitochondrial dehydrogenase complexes and, in free form, a redox-active antioxidant. Germany played a central role in translating this biochemistry into medicine, where pharmaceutical alpha-lipoic acid has long been used to treat the symptoms of diabetic neuropathy. Landmark randomized trials, including multicenter studies of intravenous and oral dosing, established much of the modern clinical interest in the compound.

Alpha-lipoic acid is well regarded as a versatile antioxidant supplement, notable for being soluble in both water and fat, which lets it act across cellular compartments where many antioxidants cannot. It is often described as a 'universal' antioxidant because its reduced form can help regenerate other protective molecules such as glutathione and vitamins C and E. Its most substantiated clinical role is in easing the symptoms of diabetic peripheral neuropathy, where controlled trials have reported meaningful reductions in pain, burning, and numbness, and it is generally well tolerated with mild nausea being the most common complaint. Enthusiasm in the broader wellness market sometimes outpaces the evidence for other uses, so it is fairly framed as strongest where the neuropathy data are, and more exploratory elsewhere.